Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L
about
The Epitranscriptome and Innate ImmunityRNA mediated Toll-like receptor stimulation in health and diseaseInfluenza A induced cellular signal transduction pathways.Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses.Stimuli-Responsive Mesoporous Silica NPs as Non-viral Dual siRNA/Chemotherapy Carriers for Triple Negative Breast Cancer.N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome densityCharacterizing exogenous mRNA delivery, trafficking, cytoplasmic release and RNA-protein correlations at the level of single cells.The genomic signature of human rhinoviruses A, B and C.Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA.Identification of Cyclobutane Pyrimidine Dimer-Responsive Genes Using UVB-Irradiated Human Keratinocytes Transfected with In Vitro-Synthesized Photolyase mRNA.Increased erythropoiesis in mice injected with submicrogram quantities of pseudouridine-containing mRNA encoding erythropoietin.Pseudouridine: still mysterious, but never a fake (uridine)!Mechanistic characterization of the 5'-triphosphate-dependent activation of PKR: lack of 5'-end nucleobase specificity, evidence for a distinct triphosphate binding site, and a critical role for the dsRBD.Developing mRNA-vaccine technologies.Sequence-engineered mRNA Without Chemical Nucleoside Modifications Enables an Effective Protein Therapy in Large Animals.RNase-L deficiency exacerbates experimental colitis and colitis-associated cancer.Transfection of pseudouridine-modified mRNA encoding CPD-photolyase leads to repair of DNA damage in human keratinocytes: a new approach with future therapeutic potentialEfficacy and immunogenicity of unmodified and pseudouridine-modified mRNA delivered systemically with lipid nanoparticles in vivo.Multi-level regulation of cellular recognition of viral dsRNA.Can't RIDD off viruses.mRNA transcript therapy.Synthetic biology devices and circuits for RNA-based 'smart vaccines': a propositional review.Emerging roles for RNA degradation in viral replication and antiviral defense.Enhancing the pharmacokinetic/pharmacodynamic properties of therapeutic nucleotides using lipid nanoparticle systems.Efficient delivery and functional expression of transfected modified mRNA in human embryonic stem cell-derived retinal pigmented epithelial cells.Type I Interferons Interfere with the Capacity of mRNA Lipoplex Vaccines to Elicit Cytolytic T Cell Responses.Modified mRNA as a therapeutic tool to induce cardiac regeneration in ischemic heart disease.Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems.Modified mRNA Vaccines Protect against Zika Virus Infection.Efficient Targeting and Activation of Antigen-Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques.Feeder-free reprogramming of human fibroblasts with messenger RNA.Efficient expression of stabilized mRNA PEG-peptide polyplexes in liver.Self-Amplifying RNA Vaccines Give Equivalent Protection against Influenza to mRNA Vaccines but at Much Lower Doses.mRNA vaccines - a new era in vaccinology.Exploring Cytotoxic mRNAs as a Novel Class of Anti-cancer Biotherapeutics.
P2860
Q26776423-9339107A-E2AA-494F-A3E4-2B2C1E0D5188Q26999252-1EFB1F99-93A5-40AC-8350-2AA76AC22453Q30353167-511EF27A-6FA6-4AC4-B224-74992F90FAD6Q30401521-DAD2A2FA-100A-4438-A83D-B7245FDF28B6Q33635355-9952E324-624A-45EB-BD7D-C93029A6AE98Q33741117-5B8615A2-250F-4E8A-AD3A-9D8E9F893875Q33878047-9FA51CF9-3FA8-44F7-9C53-79913A1EBF69Q34427165-40BDD4A3-F9A7-4F7F-9A8D-28A7A8AA8DEEQ35620919-AF965E2D-F14F-4DF1-9E36-4599F461D2C2Q35677482-D31F8D24-63B9-4596-8463-7FBEEE2912DFQ35939486-5379A0EA-5E80-45E5-AB45-370E131694F5Q36190987-441A164D-08CE-4057-BB17-4C4B9CDE067FQ36246628-C4078FA9-A083-4C71-BEB1-67E5AE379A63Q36684597-5780098E-185A-4E7A-ACF0-20E0CC06D1C1Q36757051-405A20FC-4735-429E-8D8F-A772EF001749Q36989881-FCFE830D-49C9-447E-A263-9FFE3B1330E4Q37466804-4CDB474A-1521-4E8C-B55C-62370CD3CA26Q37607987-52A5F760-C8D0-404F-AC08-A9E20DD6D9C8Q38041927-D6057682-2FD4-4A8B-9F00-4A42716B519DQ38226271-CF1C3A4C-056F-41CF-8F5B-3E0AD917F880Q38264088-A424A3F8-F1C5-4AFB-B780-57413844E194Q38310499-19480DE5-2814-41F0-8CC1-385DBE039BFFQ38365673-A90984F9-2EEC-4C63-B203-DA30271AE794Q38591825-7304965F-8CEC-4FCC-9C4E-A34D2C21F9ECQ38923727-BEA078E2-6472-4849-A1F7-B6E386388DA4Q38964752-90BA9612-FB95-424E-81D5-904734B9B86BQ39027005-3EFAB227-D6A0-4762-A4EC-45E6A530717AQ39091854-CE3AF4E5-17C1-4B8C-A2BB-B8BB5BD26140Q40049416-AD7A32C4-7FF2-4ADE-96BD-8E95E008CBA9Q41993335-8F1CA4C9-BD59-4B6A-8FDE-F4070094472DQ42238143-A3C6425E-A134-412C-A3F7-854E96E095F5Q42642506-8F1ABC03-9273-4723-B468-94B227048FEBQ47257240-466D75B3-FE02-4229-99C2-CC5162DD3467Q47736893-590CAF91-511E-4251-9A56-FE79094366F7Q52568128-BAD9D64E-A2C0-4EEB-AD78-C8DE0167347E
P2860
Nucleoside modifications in RNA limit activation of 2'-5'-oligoadenylate synthetase and increase resistance to cleavage by RNase L
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@ast
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@en
type
label
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@ast
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@en
prefLabel
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@ast
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@en
P2093
P2860
P356
P1476
Nucleoside modifications in RN ...... istance to cleavage by RNase L
@en
P2093
Bart R Anderson
Drew Weissman
Hiromi Muramatsu
Katalin Karikó
P2860
P304
P356
10.1093/NAR/GKR586
P407
P577
2011-08-03T00:00:00Z